OTC Markets OTCPK - Delayed Quote USD

GALDERMA GROUP AG (GALDY)

24.33
+0.31
+(1.29%)
At close: May 9 at 4:00:00 PM EDT
Loading Chart for GALDY
  • Previous Close 24.02
  • Open 24.02
  • Bid 23.76 x 40000
  • Ask 24.90 x 40000
  • Day's Range 24.02 - 24.02
  • 52 Week Range 15.51 - 27.20
  • Volume 453
  • Avg. Volume 10,862
  • Market Cap (intraday) 28.88B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 128.05
  • EPS (TTM) 0.19
  • Earnings Date Jul 24, 2025
  • Forward Dividend & Yield 0.04 (0.15%)
  • Ex-Dividend Date Apr 28, 2025
  • 1y Target Est 26.90

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

www.galderma.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GALDY

View More

Performance Overview: GALDY

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

GALDY
0.00%
MSCI WORLD (^990100-USD-STRD)
0.19%

1-Year Return

GALDY
46.13%
MSCI WORLD (^990100-USD-STRD)
9.31%

3-Year Return

GALDY
46.13%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

GALDY
46.13%
MSCI WORLD (^990100-USD-STRD)
80.01%

Compare To: GALDY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GALDY

View More

Valuation Measures

Annual
As of 5/9/2025
  • Market Cap

    28.46B

  • Enterprise Value

    30.76B

  • Trailing P/E

    125.41

  • Forward P/E

    44.84

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.52

  • Price/Book (mrq)

    3.71

  • Enterprise Value/Revenue

    6.93

  • Enterprise Value/EBITDA

    32.08

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.20%

  • Return on Assets (ttm)

    3.34%

  • Return on Equity (ttm)

    3.51%

  • Revenue (ttm)

    4.44B

  • Net Income Avi to Common (ttm)

    231M

  • Diluted EPS (ttm)

    0.19

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    457M

  • Total Debt/Equity (mrq)

    35.42%

  • Levered Free Cash Flow (ttm)

    131.38M

Research Analysis: GALDY

View More

Company Insights: GALDY

Research Reports: GALDY

View More

People Also Watch